PT-141: Research, Mechanism, Regulatory Context

Research overview

The story of PT-141 begins with melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) studied in the 1990s primarily for its skin-tanning effects. Researchers serendipitously discovered that melanotan II caused penile erections in male research subjects — an observation that redirected research attention toward the melanocortin system's role in sexual function. PT-141 (bremelanotide) was subsequently developed as a cyclic heptapeptide with improved properties for this application, designed to act on central melanocortin receptors rather than through the peripheral vasodilatory mechanisms of existing erectile dysfunction treatments.

Bremelanotide is a non-selective agonist at melanocortin receptors MC1, MC3, MC4, and MC5, but its effects on sexual desire are thought to be primarily mediated through MC4 receptor activation in the central nervous system. Specifically, it stimulates dopamine release in regions of the nucleus accumbens and related limbic structures involved in sexual motivation and reward. This central mechanism is distinct from peripherally-acting drugs and is particularly relevant to HSDD, a condition characterized by a subjective deficit in sexual desire causing marked personal distress, rather than a mechanical difficulty. The distinction between a desire disorder and a performance disorder makes central mechanisms pharmacologically relevant in a way that peripheral vasodilators are not.

The Phase 3 clinical program for bremelanotide — the RECONNECT trials, two identical parallel studies conducted between 2015 and 2016 — enrolled over 2,400 premenopausal women with confirmed acquired, generalized HSDD diagnoses. Primary endpoints measured change in sexual desire (via validated patient-reported outcome scales) and change in desire-related distress. Both studies met their primary endpoints with statistical significance: women receiving bremelanotide demonstrated meaningful improvements in desire scores and reductions in distress compared to placebo, with response rates of approximately 58% for bremelanotide versus 35% for placebo. The FDA approved bremelanotide on June 21, 2019 under the brand name Vyleesi, making it the second FDA-approved treatment for HSDD after flibanserin (Addyi, approved 2015).

The approved formulation is a 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and eight doses per month. The drug is not indicated for use in postmenopausal women or men, and is not a treatment for low sexual desire attributable to relationship problems, medical conditions, or medications rather than HSDD specifically. Its FDA-approved status means it can be legally prescribed and dispensed by licensed pharmacies, representing a fundamentally different regulatory position from the other compounds discussed on this educational hub.

Mechanism, in plain language

Bremelanotide acts as a non-selective agonist at melanocortin receptors (primarily MC1R, MC3R, MC4R, and MC5R). In the context of sexual desire, its therapeutically relevant mechanism is activation of MC4 receptors in the central nervous system — specifically in areas including the hypothalamus and nucleus accumbens that regulate sexual motivation and reward processing. MC4 receptor activation in these regions stimulates dopamine release, modulating the neural circuits underlying sexual desire and motivation. This contrasts sharply with peripherally-acting drugs (such as phosphodiesterase-5 inhibitors) that increase genital blood flow but do not directly address the motivational or desire-related components of sexual function. After subcutaneous injection, the drug reaches peak plasma concentrations within approximately one hour and has a terminal half-life of roughly 2.7 hours.

What has been studied

HSDD in premenopausal women — Phase 3 RECONNECT trials (two pivotal studies, n > 2,400)
Male erectile dysfunction — early Phase 2 research (intranasal formulation; this indication was not pursued to approval)
Melanocortin receptor pharmacology and central CNS sexual motivation circuits
Female sexual arousal disorder — research preceding RECONNECT program
Hamster models of female sexual behavior (published 2025, post-approval mechanistic research)

Regulatory context

Bremelanotide (Vyleesi) is an FDA-approved prescription drug — NDA 210557, approved June 21, 2019. This approval is for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) characterized by low sexual desire causing marked distress or interpersonal difficulty, and not attributable to co-existing conditions, relationship problems, or drug effects. The approval does not extend to postmenopausal women, men, or enhancement of sexual performance in people without HSDD. Because it is an approved drug, bremelanotide is not subject to the same compounding restrictions as unapproved peptides; it can be prescribed through standard pharmacy channels. Any compounded versions of bremelanotide should be evaluated carefully, as they would not carry the same quality assurances as the FDA-approved product.

Considerations

The RECONNECT trials documented a well-characterized adverse effect profile. Nausea was the most common adverse effect (approximately 40% of bremelanotide recipients vs. 1.3% placebo), followed by facial flushing (approximately 20%) and headache (approximately 11%). Approximately 8% of users discontinued treatment due to adverse events. Clinically meaningful blood pressure increases were observed transiently following injection — the drug is contraindicated in individuals with uncontrolled hypertension or cardiovascular disease. Prescribers should screen appropriately at baseline. A maximum of eight doses per month is recommended, with at least 24 hours between doses. Hyperpigmentation, particularly of the face, gums, and breasts, has been observed with chronic use as a class effect of melanocortin receptor agonists. Patients should be counseled about all of these considerations in the context of a complete clinical evaluation.